Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Erasca, Inc. (ERAS)

Erasca Receives FDA Fast Track Designation for ERAS-0015 in Pancreatic Cancer

Positive Impact 3 of 5 product/contract Written later

Erasca announced that the FDA granted Fast Track Designation to ERAS-0015 for metastatic pancreatic adenocarcinoma. The designation can allow more frequent FDA interactions and may expedite review, but it does not change approval standards or increase the likelihood of U.S. marketing approval.

Key points

  • FDA granted Fast Track Designation to ERAS-0015 for metastatic pancreatic adenocarcinoma, announced August 24, 2026.
  • Designated programs may gain more frequent FDA interactions and may be eligible for accelerated approval, priority review, or rolling review if criteria are met.
  • The FDA may later revoke the designation or decide review timing will not be shortened.
  • The company plans a phase 3 trial in pancreatic cancer and two potentially registration-enabling lung cancer trials.

The filing

CompanyErasca, Inc. (ERAS)
Form8-K, current report
Filed with the SECAug 24, 2026, 8:15 AM ET
Accession number0001193125-26-361895

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 24, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.